Bass challenges second Tecfidera patent

Hedge fund manager Kyle Bass filed a new patent challenge on Friday against multiple sclerosis (MS) drug Tecfidera dimethyl fumarate from Biogen Inc. (NASDAQ:BIIB), the latest in a string of challenges to marketed drugs and his second challenge of Tecfidera.

The Coalition for Affordable Drugs V, an entity associated with Bass, filed an inter partes review (IPR) with the U.S. Patent and Trademark Office challenging U.S. Patent No. 8,399,514, which covers Tecfidera and expires in 2028. The '514 patent is the last to expire among seven Orange Book-listed patents covering Tecfidera. ...